BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset

PartnershipPositive

AI Analysis

Summary

BoomRay Pharmaceuticals announced an exclusive global license agreement with Novartis for a novel radioligand therapy asset for precision oncology diagnostics and therapeutics. The partnership marks a significant collaboration for BoomRay's innovative RLT platform.

Importance:7/10

Sentiment:

0.70

Radioligand TherapyLicensing AgreementOncologyPrecision MedicineNovartis Partnership

Related Companies

$NVS

Read the original article

Published by PR Newswire Biotech on September 22, 2026 4:00 AM

Read Original